rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

John C. Jacobs

President and CEO

Company insider

Files Form 4 as: President and CEO, Novavax; President, CEO, Harmony Biosciences Holdings.

Every Form 4 they filed

In numbers

Trades disclosed
76
Buys
0
Sells
10
Bought
$0
Sold
$8.8M
Companies
2
Companies where not an officer
0
First trade
18 Aug 2020
Last trade
3 Mar 2026
Last filed
9 Mar 2026

Companies traded

Where they are an officer
NVAX NovavaxDirector, Officer · Biotechnology · last 3 Mar 20260 buys · 0 sells
HRMY Harmony Biosciences HoldingsDirector, Officer · Pharmaceuticals · last 15 Aug 20220 buys · 10 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
3 Mar 2026filed 5 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—150,167 at $0.00filing
3 Mar 2026filed 5 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code F$658K69,288 at $9.49filing
3 Mar 2026filed 5 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—150,167 at $0.00filing
3 Mar 2026filed 5 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—150,167 at $0.00filing
3 Mar 2026filed 5 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—150,167 at $0.00filing
3 Mar 2026filed 5 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code F$658K69,288 at $9.49filing
2 Mar 2026filed 9 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—551,500 at $0.00filing
2 Mar 2026filed 9 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—551,500 at $0.00filing
2 Mar 2026filed 3 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—367,500 at $0.00filing
2 Mar 2026filed 3 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A$5.0M551,500 at $9.09filing
2 Mar 2026filed 3 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A—367,500 at $0.00filing
2 Mar 2026filed 3 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code A$5.0M551,500 at $9.09filing
1 Mar 2026filed 3 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—83,333 at $0.00filing
1 Mar 2026filed 3 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code F$390K38,450 at $10.14filing
1 Mar 2026filed 3 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—83,333 at $0.00filing
1 Mar 2026filed 3 Mar 2026NVAX Novavaxoption or derivative · BiotechnologySEC FORM 4 Code M—83,333 at $0.00filing
1 Mar 2026filed 3 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—83,333 at $0.00filing
1 Mar 2026filed 3 Mar 2026NVAX NovavaxBiotechnologySEC FORM 4 Code F$390K38,450 at $10.14filing
23 Jan 2026filed 26 Jan 2026NVAX NovavaxBiotechnologySEC FORM 4 Code M—83,197 at $0.00filing
23 Jan 2026filed 26 Jan 2026NVAX NovavaxBiotechnologySEC FORM 4 Code F$359K39,132 at $9.17filing

Sectors

Health Care10

Buys in green, sells in red, by the company’s sector.

Related people

Kumar BudurChief Medical Officer · Chief Medical Officer at Harmony Biosciences Holdings, filing Form 4 there in the last year
Rachel K. KingDirector · Director at Novavax, filing Form 4 there in the last year
John W. ShiverDirector · Director at Novavax, filing Form 4 there in the last year
Gregg H. AltonDirector · Director at Novavax, filing Form 4 there in the last year
Charles W. NewtonDirector · Director at Novavax, filing Form 4 there in the last year